CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 92 enrolled
Drug / intervention
Ceevra Revealdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03334344
NCT03334344N/ACompleted

Using Virtual Reality (VR) Models for Preoperative Planning

Ceevra, Inc.·interventional·Posted Nov 7, 2017·Updated Aug 29, 2024

In Brief

A clinical study evaluating Ceevra Reveal for Kidney Cancer and Renal Cell Carcinoma. Completed, enrolled 92 participants across 6 sites.

Detailed Summary

A prospective, randomized, controlled study designed to assess whether digital virtual reality (VR) models, created from existing CT scans and MRIs, provide surgeons with an improved understanding of their patients' anatomy, resulting in more efficient operations (robotic partial nephrectomy) and improved patient care.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedNov 7, 2017
Enrollment StartOct 24, 2017
Primary CompletionFeb 28, 2019
Study CompletionMar 18, 2019
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 8.7 years ago

Interventions

Ceevra Revealdevice

VR models generated using Ceevra Reveal are viewed by surgeons in connection with the case in addition to source CT/MR image.